OBJECTIVE To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone. RESEARCH DESIGN AND METHODS Treatment-naive patients or those receiving metformin, sulfonylurea, or thiazolidinedione entered a 10-week pioglitazone dose-optimization period with only pioglitazone. They ...

more than 10 million people worldwide are living with parkinson’s disease (pd). the ages of people who have parkinson are variable, usually between 50 and 80 years, the average of them is 55 years old. the symptoms of pd are progressive, and within 10 to 20. it happens when dopaminergic neurons were being degenerate. peripheral and central inflammatory and oxidative stress pathways play a compl...

pioglitazone belongs to the thiazolidinedione (tzd) class of antidiabetic agents, with proven efficacy in increasing insulin sensitivity and in the treatment of type 2 diabetes mellitus in humans. pioglitazone has been proposed as a potential feed additive to reduce insulin resistance and consequently some of the metabolic disorders in transition cows. this study was aimed at determining the...

background : non-alcoholic steatohepatitis (nash) is a common liver disease that, in the absence of treatment may progress to cirrhosis. there is a strong association of nash with insulin resistance; thus insulin sensitizer drugs have been used for this disease. the aim of this study was to compare the effect of pioglitazone with metformin on liver transaminases, the homa index, and adiponectin...

 Objective: In obesity, chronic low grade inflammation, created by induction of pro-inflammatory markers, causes adipocyte dysfunction in adipose tissue. Adipocytes dysfunction is associated with various diseases including insulin resistance and obesity. In obesity, inflammatory factors such as osteopontin (OPN), angiopoietin-like protein 2 (Angptl2) and transforming growth factor-β (TGF-β) are...

The effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on hypertensive cardiovascular injury is unknown. We examined the effect of pioglitazone on hypertensive cardiovascular injury and the significance of combination of pioglitazone with angiotensin type 1 receptor blocker. Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, can...

background: pioglitazone from thiazolidinediones generation, represent a new antidiabetic drugs that have been introduced in the world recently. thiazolidinediones can improve insulin resistance by activating the nuclear peroxoxisome proliferator activated receptor-γ (ppar-γ) and increasing insulin sensitivity in their receptors. insulin and its receptors are found in specific areas of cns with...

BACKGROUND AND AIMS Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary prevention of CVD. METHODS Randomized-controlled trials of pioglitazone in patients with CVD were identified through PubMed, Embase, Cochrane a...

OBJECTIVE Peroxisome proliferator activated receptor γ-activating drugs show various salutary effects in preclinical models of neurodegenerative disease. The decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-oriented data sources. METHODS Using observational data from 2004-2010, we analyzed the association of pioglitazone and incidence of dementia...

Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. In this study, we demonstrated suppression of body weight gain in response to pioglitazone administration by combination therapy of pioglitazone ...